This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

A possible new treatment for elevated Lp(a) in CVD - HORIZON

  • Research type

    Research Study

  • Full title

    A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).

  • IRAS ID

    267092

  • Contact name

    Azfar Zaman

  • Contact email

    azfar.zaman@nhs.net

  • Sponsor organisation

    Novartis Pharma AG

  • Eudract number

    2019-001076-11

  • Clinicaltrials.gov Identifier

    NCT04023552

  • Duration of Study in the UK

    3 years, 7 months, 3 days

  • Research summary

    Lipoprotein (a) is recognised as an independent risk factor biomarker for Cardiovascular Disease. This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a). The study population will consist of subjects with established CVD; 7,680 males and females; age 18 to 80 years both inclusive.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    20/NW/0310

  • Date of REC Opinion

    17 Sep 2020

  • REC opinion

    Further Information Favourable Opinion